Host Kinase CSNK2 is a Target for Inhibition of Pathogenic SARS-like β-Coronaviruses.


Journal

ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906

Informations de publication

Date de publication:
15 07 2022
Historique:
pubmed: 21 6 2022
medline: 19 7 2022
entrez: 20 6 2022
Statut: ppublish

Résumé

Inhibition of the protein kinase CSNK2 with any of 30 specific and selective inhibitors representing different chemotypes, blocked replication of pathogenic human, bat, and murine β-coronaviruses. The potency of in-cell CSNK2A target engagement across the set of inhibitors correlated with antiviral activity and genetic knockdown confirmed the essential role of the CSNK2 holoenzyme in β-coronavirus replication. Spike protein endocytosis was blocked by CSNK2A inhibition, indicating that antiviral activity was due in part to a suppression of viral entry. CSNK2A inhibition may be a viable target for the development of anti-SARS-like β-coronavirus drugs.

Identifiants

pubmed: 35723434
doi: 10.1021/acschembio.2c00378
pmc: PMC9236220
doi:

Substances chimiques

Antiviral Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1937-1950

Subventions

Organisme : NIDDK NIH HHS
ID : U24 DK116204
Pays : United States

Commentaires et corrections

Type : UpdateOf

Références

PLoS Pathog. 2020 Mar 9;16(3):e1008392
pubmed: 32150576
J Clin Invest. 2017 Apr 3;127(4):1338-1352
pubmed: 28240606
Org Biomol Chem. 2021 May 26;19(20):4380-4396
pubmed: 34037044
Virus Evol. 2016 Jun 10;2(1):vew014
pubmed: 28694997
J Biol Chem. 2021 Jan-Jun;296:100306
pubmed: 33476648
Science. 2021 Feb 19;371(6531):823-829
pubmed: 33495307
J Transl Med. 2020 Oct 15;18(1):390
pubmed: 33059719
Signal Transduct Target Ther. 2021 May 17;6(1):183
pubmed: 33994545
J Med Chem. 2022 Jan 27;65(2):935-954
pubmed: 33970631
Nat Rev Drug Discov. 2017 Apr;16(4):285-296
pubmed: 28104905
ACS Chem Biol. 2021 Apr 16;16(4):579-585
pubmed: 33745272
Bioorg Med Chem Lett. 2007 Aug 1;17(15):4191-5
pubmed: 17540560
J Med Chem. 2004 Dec 2;47(25):6239-47
pubmed: 15566294
J Med Chem. 2019 Jun 27;62(12):5810-5831
pubmed: 31136173
J Biol Chem. 1991 Oct 25;266(30):20380-9
pubmed: 1939094
Methods Enzymol. 2008;438:77-93
pubmed: 18413242
Science. 2021 Jul 30;373(6554):541-547
pubmed: 34326236
FASEB J. 2003 Mar;17(3):349-68
pubmed: 12631575
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Nat Rev Microbiol. 2021 Mar;19(3):155-170
pubmed: 33116300
J Virol. 2005 Mar;79(6):3846-50
pubmed: 15731278
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Clin Microbiol Rev. 2020 May 13;33(3):
pubmed: 32404434
ACS Med Chem Lett. 2012 Jan 24;3(4):278-83
pubmed: 24900464
J Biol Chem. 1995 Oct 27;270(43):25872-8
pubmed: 7592773
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
PLoS Pathog. 2014 Nov 06;10(11):e1004502
pubmed: 25375324
Molecules. 2021 Mar 31;26(7):
pubmed: 33807474
EMBO J. 2021 Aug 16;40(16):e107821
pubmed: 34159616
Nature. 2013 Mar 14;495(7440):251-4
pubmed: 23486063
ACS Med Chem Lett. 2019 Oct 23;11(3):340-345
pubmed: 32184967
Int J Mol Sci. 2021 Jan 08;22(2):
pubmed: 33429995
Sci Transl Med. 2020 Apr 29;12(541):
pubmed: 32253226
Cell Chem Biol. 2018 Feb 15;25(2):206-214.e11
pubmed: 29174542
J Med Chem. 2019 Mar 14;62(5):2830-2836
pubmed: 30768268
Bioorg Med Chem Lett. 2020 Aug 15;30(16):127284
pubmed: 32631507
Cell. 2020 Aug 6;182(3):685-712.e19
pubmed: 32645325
Cell. 2022 Apr 14;185(8):1414-1430.e19
pubmed: 35325595
Bioorg Med Chem Lett. 2021 Nov 15;52:128407
pubmed: 34624490
Proc Natl Acad Sci U S A. 2016 Mar 15;113(11):3048-53
pubmed: 26976607
Nat Chem Biol. 2015 Aug;11(8):536-41
pubmed: 26196764
Viruses. 2020 Aug 12;12(8):
pubmed: 32806708
Cell Rep. 2021 Jul 13;36(2):109364
pubmed: 34214467
Nat Med. 2015 Dec;21(12):1508-13
pubmed: 26552008
Cell Chem Biol. 2021 Apr 15;28(4):546-558.e10
pubmed: 33484635
J Biol Chem. 1992 Jul 15;267(20):13943-51
pubmed: 1629192
Semin Oncol. 2018 Jan;45(1-2):58-67
pubmed: 30318085
Rev Med Virol. 2012 May;22(3):166-81
pubmed: 22113983
Nat Rev Mol Cell Biol. 2022 Jan;23(1):3-20
pubmed: 34611326
ACS Chem Biol. 2012 Nov 16;7(11):1848-57
pubmed: 22894855
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
PLoS Pathog. 2019 May 15;15(5):e1007788
pubmed: 31091289
Biochem J. 2003 Jan 1;369(Pt 1):1-15
pubmed: 12396231
Cell Mol Life Sci. 2009 Jun;66(11-12):1817-29
pubmed: 19387552
Methods Mol Med. 2005;107:183-206
pubmed: 15492373
Traffic. 2013 Dec;14(12):1272-89
pubmed: 24025110
Cell Rep. 2020 Jul 21;32(3):107940
pubmed: 32668216
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
J Transl Med. 2020 Aug 18;18(1):319
pubmed: 32811513
Science. 2020 Dec 4;370(6521):
pubmed: 33060197

Auteurs

Xuan Yang (X)

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.

Rebekah J Dickmander (RJ)

Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Armin Bayati (A)

Structural Genomics Consortium, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.

Sharon A Taft-Benz (SA)

Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Jeffery L Smith (JL)

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Carrow I Wells (CI)

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Emily A Madden (EA)

Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Jason W Brown (JW)

Takeda San Diego, San Diego, California 92121, United States.

Erik M Lenarcic (EM)

Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Boyd L Yount (BL)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Edcon Chang (E)

Takeda San Diego, San Diego, California 92121, United States.

Alison D Axtman (AD)

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.

Ralph S Baric (RS)

Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Mark T Heise (MT)

Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Peter S McPherson (PS)

Structural Genomics Consortium, Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC H3A 2B4, Canada.

Nathaniel J Moorman (NJ)

Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.
Department of Microbiology & Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.

Timothy M Willson (TM)

Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
Rapidly Emerging Antiviral Drug Development Initiative (READDI), Chapel Hill, North Carolina 27599, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH